REG - Alliance Pharma PLC - Further update on timing of preliminary results

Alliance PharmaAnnouncement

22/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240422:nRSV4157La&default-theme=true

RNS Number : 4157L  Alliance Pharma PLC  22 April 2024

 

 For immediate release  22 April 2024

 

 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

 

Further update on timing of preliminary results announcement

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that the preliminary results for the year ended 31 December 2023 will not be
published on 23 April 2024. We now anticipate that the results will be
published in early May, and we expect to provide an update on the date of
publication on 26 April 2024.

 

Further to the announcement on 5 April 2024, whilst the audit of the results
is at an advanced stage, the Group's auditor, Deloitte LLP, has requested
additional time to finalise its work.

 

Alliance reiterates that the details provided in the full year trading update
on 29 January 2024 remain accurate.

 

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Sophie Wills
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Deutsche Numis (Nominated Adviser and Joint Broker)                       + 44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Sher Shah

 Investec Bank plc (Joint Broker)                                          + 44 (0)20 7597 5970
 Patrick Robb / Maria Gomez de Olea

 

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.

 

We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.

 

Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands.

 

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FURZZGZDRMMGDZM